Replication Data for: Quality control of cervical cytology using a 3-type HPV mRNA test increases screening program sensitivity of cervical intraepithelial neoplasia grade 2+ in young Norwegian women – a cohort studydoi:10.18710/TDJV8XDataverseNO2019-11-151Skjeldestad, Finn Egil, 2019, "Replication Data for: Quality control of cervical cytology using a 3-type HPV mRNA test increases screening program sensitivity of cervical intraepithelial neoplasia grade 2+ in young Norwegian women – a cohort study", https://doi.org/10.18710/TDJV8X, DataverseNO, V1, UNF:6:M7dRklbtWaDqpYHrG432PA== [fileUNF]Replication Data for: Quality control of cervical cytology using a 3-type HPV mRNA test increases screening program sensitivity of cervical intraepithelial neoplasia grade 2+ in young Norwegian women – a cohort studydoi:10.18710/TDJV8XSkjeldestad, Finn EgilUiT The Arctic University of Norway2019-11-05DataverseNOUiT The Arctic University of NorwaySkjeldestad, Finn EgilSkjeldestad, Finn Egil2019-11-13Medicine, Health and Life SciencesCervical cytologyCervical cancerScreeningCytologymRNAHPV genotypesValidationThe dataset comprise the variables necessary to replicate the results published.</P>Abstract: Within 2021, Norway intends to complete implementation of HPV DNA-based primary screening for cervical cancer for women 34-69 years, while continue cytology-based screening for women 25-33 years. Over the recent years, the incidence of cervical cancer has increased by 30% among women younger than 40 years. In this subset of women, nearly 30% were diagnosed with a normal smear, as most recent smear, prior the cancer diagnosis. This observation demands quality control of normal smears. The aim of this study was to assess increase in program sensitivity of CIN2+ after follow-up of women with false negative Pap-smears testing positive for a 3-type (-16, -18, -45) HPV mRNA test in a cohort design over one screening interval. 521 women, aged 23-39 years, and no prior history of CIN1+ or HSIL, with an ASC-US or worse smear (ASC-US+) and 1444 women with normal screening cytology comprised the study cohorts. The positivity rate for the 3-type HPV mRNA was 1.9% (28/1444). Rescreening revealed 23 women with ASC-US, two women with LSIL, two women with ASC-H, and one woman with AGUS. If the HPV mRNA-positivity rate and histology findings from samples rescreened were applied to all women with normal cytology, an estimated increase in screening sensitivity of 16.4% (95% CI:15.3 -17.5) for CIN2+ and 17.3% (95% CI:16.2-18.4) for CIN3+ were achieved. By rescreening less than 2% of women with normal cytology positive for a 3-type HPV mRNA test, we achieved a significant increase in screening program sensitivity.Westre B, Giske A, Guttormsen H, Wergeland Sørbye S, Skjeldestad FE (2019) Quality control of cervical cytology using a 3-type HPV mRNA test increases screening program sensitivity of cervical intraepithelial neoplasia grade 2+ in young Norwegian women—A cohort study.10.1371/journal.pone.0221546Westre B, Giske A, Guttormsen H, Wergeland Sørbye S, Skjeldestad FE (2019) Quality control of cervical cytology using a 3-type HPV mRNA test increases screening program sensitivity of cervical intraepithelial neoplasia grade 2+ in young Norwegian women—A cohort study.Quality_control_cervical_cytology.tab436611text/tab-separated-valuesUNF:6:M7dRklbtWaDqpYHrG432PA==Continuous4.689661459401187.31.36601007787445623.039.04366.00.031.0UNF:6:1CRPNEEjSVkDAgpo1atvwA==Prim scr0.73806722122128691.01.0.0.01.5852038479157284366.04.03ASCUS LSIL4521Norm cyt - SEE24012Norm cyt SEE14444HSIL69UNF:6:LX8I7X847Tzeb2bsDROK6Q==Rescreening1.01.01458060721933664366.0.5.00.01.71094823637198861.04ASCU, LSIL4522Norm, see neg14163Norm, see pos285HSIL691Norm, See (-)2401UNF:6:BLb8FkKOlODCK4QCatnlRA==Primary cytology0.177737059092983826.00.04366.0.-1.00.00.57637251742398176ACIS1-1Unsat27Sq CC05AGUS11ASC-US3704ASC-H329ca usp03HSIL352LSIL8211metast00Norm38438adeno ca0UNF:6:sSBx/4t8IDWbbLWVqJH8dQ==Cytology rescre SEE pos0.18666972056801923.0.06.00.59027323506659380.0-1.04366.04ASC-H3411metast08adeno ca0-1Uegnet23HSIL355AGUS22LSIL830Norm38151ASC-US3946ACIS19ca usp07Sq CC0UNF:6:AoUY8HMEjM4RsCZqigi2bA==SEE positivity1.0-1.0-0.5950526797984481-1.00.04366.00.5377082457901851.UNF:6:1OVJPPx2tAEE5d/WyFohRA==HPV 162703.00.040288634996994610.196694497391187471.00.01663.00.0.UNF:6:oHvX+LRghwOCpBapve0TEQ==HPV 180.02703.0.0.00.0222489476849064940.147536507415119951663.01.0UNF:6:yHmZwGUs5ZNKb8ddhF+I0Q==HPV 450.0048105832832229331663.02703.0.0.01.00.00.06921215284996186UNF:6:9pBWLSor/m+dKS+Mv2LZog==Indication biopsy0.04366.00.01.00.27989624857915010.08566193311956444.0.0UNF:6:8RQryfZXkggJD2L85prqYA==Status end of study.5.6687596887688014366.00.028.00.0-1.01.368987631699566421CIN 1470Back to scr275126ACIS928adeno cc125AGUS2-1no attend116323CIN 314420Normal biop604incompl f-up15827Sq cc322CIN 228UNF:6:axUuBmMRyeXz8Ee96g0mYg==00_ReadMe.pdfapplication/pdf